SCHEMBL579950

SCHEMBL579950

Cc1ccc2c(C(N)=O)cn(O)c2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.39
ICMT O60725 1/20 0.39
CNR2 P34972 1/20 0.39
MAP2K2 P36507 1/20 0.39
MAP2K1 Q02750 1/20 0.39
PARP1 P09874 1/20 0.38
TLR8 Q9NR97 1/20 0.38
GRM2 Q14416 1/20 0.37
DAO P14920 1/20 0.37
KDM4E B2RXH2 2/20 0.36
MAPT P10636 2/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
HSD17B10 Q99714 1/20 0.35
ADRA1D P25100 1/20 0.35
KCNMA1 Q12791 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
DYRK3 O43781 1/20 0.34
ROCK2 O75116 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL579403 0.83 MAP2K2 (0.40) CNR1ICMTCNR2MAP2K2MAP2K1
SCHEMBL10193361 0.81 CNR1 (0.46) CNR1ICMTCNR2MAP2K2MAP2K1
SCHEMBL10341192 0.79 KDM4E (0.49) MAP2K2MAP2K1KDM4EALDH1A1LMNA
SCHEMBL28131995 0.76 ICMT (0.47) CNR1ICMTMAP2K2MAP2K1KDM4E
SCHEMBL10596904 0.74 KDM4E (0.50) CNR1KDM4EMAPTALDH1A1LMNA
SCHEMBL9919096 0.73 BRD4 (0.50) MAP2K2MAP2K1KDM4EMAPT
SCHEMBL28131233 0.71 ICMT (0.55) CNR1ICMTCNR2MAP2K2MAP2K1
SCHEMBL10254311 0.70 KMT2A (0.49) KDM4EMAPTALDH1A1LMNAHSD17B10
SCHEMBL14756161 0.70 BRD4 (0.49) KDM4EMAPTALDH1A1LMNAHSD17B10
SCHEMBL19971408 0.70 MAP2K1 (0.47) CNR1CNR2MAP2K2MAP2K1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735414-B2 Indole derivatives and methods for antiviral treatment PTC THERAPEUTICS, INC. (US) 2014-05-27 US disclosed
US-20120184574-A1 INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT PTC THERAPEUTICS, INC. (US) 2012-07-19 US disclosed
EP-2417122-A1 INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT PTC Therapeutics, Inc. (US) 2012-02-15 EP disclosed
WO-2010117932-A1 INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT SCHERING CORPORATION (US) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184574-A1 INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT IDO1, IRF3, MAVS CNR1 522/4885ICMT 200/4885CNR2 567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.